News
KalVista Aktie: Insider verkaufen für 265.000 Dollar
Die KalVista Pharmaceuticals-Aktie notiert derzeit bei 14,11 Dollar und verzeichnet damit ein Plus von…
Der Beitrag KalVista Aktie: Insider verkaufen für 265.000 Dollar erschien zuerst auf kapitalma
KalVista-Aktie: Finanzspritze mit Bitterstoff
Ein neuer Kapitalmarkt-Deal sorgt bei KalVista für gemischte Gefühle. Während das Biotech-Unternehmen seine Kriegskasse…
Der Beitrag KalVista-Aktie: Finanzspritze mit Bitterstoff erschien zuerst auf
Viatris Aktie: Kommt die Trendwende?
Nach einer langen Talfahrt zeigt die Viatris-Aktie endlich wieder Lebenszeichen. Der Grund: Der Pharmakonzern…
Der Beitrag Viatris Aktie: Kommt die Trendwende? erschien zuerst auf kapitalmarktexpert
Viatris Aktie: Kommt die Trendwende?
Nach einer langen Talfahrt zeigt die Viatris-Aktie endlich wieder Lebenszeichen. Der Grund: Der Pharmakonzern…
Der Beitrag Viatris Aktie: Kommt die Trendwende? erschien zuerst auf kapitalmarktexpert
Astrazeneca Stock: Breakthrough Drug Study Boosts Shares
The British pharmaceutical giant saw its shares surge on Monday, reaching the highest level since mid-June following positive Phase III trial results for its experimental drug Baxdrostat. The
Astrazeneca Stock: Breakthrough Drug Study Boosts Shares
The British pharmaceutical giant saw its shares surge on Monday, reaching the highest level since mid-June following positive Phase III trial results for its experimental drug Baxdrostat. The
KalVista Posts 154% Expense Jump in Q1
KalVista Pharmaceuticals (NASDAQ:KALV), a biopharmaceutical company developing and commercializing therapies for rare diseases, announced its earnings for the first quarter of fiscal 2026 on Sept
Adaptimmune Sales Jump 59 Percent
Adaptimmune Therapeutics Plc (NASDAQ:ADAP), a biotechnology company specializing in engineered T-cell therapies for cancer, released its second-quarter earnings on August 13, 2025, covering results
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript
Image source: The Motley Fool.
Amarin Plc (NASDAQ: AMRN)Q4 2024 Earnings CallMar 12, 2025, 8:00 a.m. ET
Operator
Source Fool.com
Viatris Misses Estimates, Cash Flow Up
Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt
Viatris Misses Estimates, Cash Flow Up
Viatris (NASDAQ:VTRS), a global healthcare company known for its broad portfolio of pharmaceutical products, released its fourth-quarter 2024 results on Feb. 27. Despite achieving substantial debt
LivaNova to Announce Second-Quarter 2025 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug. 6, 2025, at 1 p.m. London time (8 a.m
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with drug-resistant epilepsy (DRE)
CORE-VNS Study Further Validates Effectiveness of LivaNova’s VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced completion of the CORE-VNS study, evaluating comprehensive outcomes of real-world evidence for more than
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it has initiated the process with the U.S. Centers for Medicare and Medicaid Services (CMS) to seek
LivaNova to Present at the Jefferies Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside chat at the Jefferies Global
LivaNova Reports First-Quarter 2025 Results; Updates 2025 Guidance
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the first quarter ended March 31, 2025 and updated full-year 2025 guidance.
Financial Summary
LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced 12-month, top-line data from its OSPREY randomized controlled trial (RCT), evaluating outcomes with the
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) and reminds investors of the June
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Viatris
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Viatris, Inc. (“Viatris” or the “Company”) (NASDAQ: VTRS) and reminds investors of the June
LivaNova to Announce First-Quarter 2025 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2025 results on Wednesday, May 7, 2025 at 1 p.m. London time (8
LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2024 results and issued full-year 2025 guidance.
Financial Summary and
LivaNova to Present at the Barclays Global Healthcare Conference
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will present in a fireside chat at the Barclays Global
LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2024 results on Tuesday, February 25, 2025 at 1
LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer
LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Natalia Kozmina is joining the Company as Chief Human Resources Officer (CHRO), effective January 14